Clinical Trial Update: Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects [Phase 4]

View source ↗

Summary

Phase 4 study evaluating switching HIV-1 infected patients with neurocognitive or neuropsychological side effects from efavirenz/Atripla to rilpivirine to asses…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
• EFAVIRENZ (efavirenz)
• rilpivirine (rilpivirine)

Snippet

Sponsor: Azienda Ospedaliera San Gerardo di Monza | Conditions: Impaired Cognition, Depression/Anxiety | Phase 4 | Status: COMPLETED